BG102438A - Medicamentous form - Google Patents

Medicamentous form

Info

Publication number
BG102438A
BG102438A BG102438A BG10243898A BG102438A BG 102438 A BG102438 A BG 102438A BG 102438 A BG102438 A BG 102438A BG 10243898 A BG10243898 A BG 10243898A BG 102438 A BG102438 A BG 102438A
Authority
BG
Bulgaria
Prior art keywords
medicamentous form
medicamentous
vitromodels
formguarantees
activemedicamentous
Prior art date
Application number
BG102438A
Other languages
Bulgarian (bg)
English (en)
Inventor
Ross MACRAE
Janet Smith
Original Assignee
Pfizer Research And Development Company, N.V./S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Research And Development Company, N.V./S.A. filed Critical Pfizer Research And Development Company, N.V./S.A.
Publication of BG102438A publication Critical patent/BG102438A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BG102438A 1995-11-21 1998-05-08 Medicamentous form BG102438A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9523752.5A GB9523752D0 (en) 1995-11-21 1995-11-21 Pharmaceutical formulations
PCT/EP1996/005020 WO1997018814A1 (en) 1995-11-21 1996-11-11 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
BG102438A true BG102438A (en) 1999-01-29

Family

ID=10784188

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102438A BG102438A (en) 1995-11-21 1998-05-08 Medicamentous form

Country Status (29)

Country Link
EP (1) EP0862437A1 (xx)
JP (1) JPH10513481A (xx)
KR (1) KR19990071505A (xx)
CN (1) CN1215993A (xx)
AP (1) AP718A (xx)
AR (1) AR004335A1 (xx)
AU (1) AU709560B2 (xx)
BG (1) BG102438A (xx)
BR (1) BR9611626A (xx)
CA (1) CA2232715A1 (xx)
CO (1) CO4480020A1 (xx)
CZ (1) CZ155498A3 (xx)
GB (1) GB9523752D0 (xx)
HR (1) HRP960554A2 (xx)
HU (1) HUP9903734A3 (xx)
IS (1) IS4706A (xx)
MA (1) MA26410A1 (xx)
MX (1) MX9804008A (xx)
NO (1) NO982302L (xx)
NZ (1) NZ322053A (xx)
OA (1) OA10687A (xx)
PE (1) PE22898A1 (xx)
PL (1) PL326981A1 (xx)
SK (1) SK63098A3 (xx)
TN (1) TNSN96141A1 (xx)
TR (1) TR199800902T2 (xx)
WO (1) WO1997018814A1 (xx)
YU (1) YU62096A (xx)
ZA (1) ZA969722B (xx)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ504487A (en) * 1997-12-16 2002-11-26 Pfizer Prod Inc Combination of alpha-adrenergic antagonists and cGMP elevators for the treatment of impotence
CA2320900C (en) 1998-03-19 2009-10-27 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
GT199900061A (es) * 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
EP0987020A1 (en) * 1998-09-04 2000-03-22 Pharma Pass LLC Metoprolol composition and processes for manufacturing the same
EP0974343B1 (en) * 1998-07-22 2004-09-29 Pharma Pass II LLC Process for manufacturing a solid metoprolol composition
CO5140079A1 (es) * 1998-10-14 2002-03-22 Novartis Ag Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
US20030059467A1 (en) * 2001-09-14 2003-03-27 Pawan Seth Pharmaceutical composition comprising doxasozin
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2005037247A2 (en) * 2003-10-17 2005-04-28 Ranbaxy Laboratories Limited Oral matrix formulations of doxazosin
US20050255157A1 (en) * 2004-05-11 2005-11-17 Glenmark Pharmaceuticals Limited Sustained release, mucoadhesive vaginal pharmaceutical compositions
KR100574554B1 (ko) * 2004-05-28 2006-04-27 한미약품 주식회사 니아신의 경구투여용 서방성 조성물
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
KR100679111B1 (ko) * 2004-11-20 2007-02-07 대우약품공업주식회사 독사조신을 포함하는 서방성 정제
RU2442574C2 (ru) * 2005-08-22 2012-02-20 Новартис Аг ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ pН-ЗАВИСИМОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, МОДИФИКАТОР pН И ЗАМЕДЛЯЮЩИЙ АГЕНТ
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
ES2360423T3 (es) 2006-04-26 2011-06-03 Supernus Pharmaceuticals, Inc. Preparaciones de liberación controlada de oxcarbazepina que tienen perfil de liberación sigmoidal.
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
UA97244C2 (xx) 2006-05-04 2012-01-25 Берингер Ингельхайм Интернациональ Гмбх Поліморфи 1-$(4-метилхіназолін-2-іл)метил]-3-метил-7-(2-бутин-1-іл)-8-(3-(r)-амінопіперидин-1-іл)ксантину$полиморфы 1-$(4-метилхиназолин-2-ил)метил]-3-метил-7-(2-бутин-1-ил)-8-(3-(r)-аминопиперидин-1-ил)ксантина
CN100396282C (zh) * 2006-07-25 2008-06-25 山东省医药工业研究所 甲磺酸多沙唑嗪缓释胶囊及制备方法
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
EP2262484B1 (en) 2008-03-11 2013-01-23 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR101004205B1 (ko) * 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
EP3711751A1 (en) 2009-02-13 2020-09-23 Boehringer Ingelheim International GmbH Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
US8828953B2 (en) 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
AU2010239311B2 (en) 2009-04-20 2014-05-22 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
KR20190071840A (ko) 2009-11-27 2019-06-24 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US20110150989A1 (en) * 2009-12-22 2011-06-23 Mallinkckrodt Inc. Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
ES2935300T3 (es) 2010-05-05 2023-03-03 Boehringer Ingelheim Int Combiterapia
CA2804926C (en) 2010-07-09 2019-01-08 James Trinca Green Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin
JP2013540156A (ja) 2010-10-19 2013-10-31 エルセリクス セラピューティクス インコーポレイテッド 化学感覚受容体リガンドに基づく治療法
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
EA039943B1 (ru) 2011-01-07 2022-03-30 Анджи Фарма (Юс) Элэлси Способ снижения уровней глюкозы в крови у субъекта
CN102058555A (zh) * 2011-01-13 2011-05-18 北京汇诚瑞祥医药技术有限公司 一种多沙唑嗪控释片
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
CN102188431A (zh) * 2011-05-09 2011-09-21 浙江九旭药业有限公司 甲磺酸多沙唑嗪缓释片及其制备方法
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3003297A4 (en) 2013-06-05 2017-04-19 Synchroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
CN105616378A (zh) * 2014-10-31 2016-06-01 康普药业股份有限公司 一种氟康唑胶囊及其制备方法
EP3468562A1 (en) 2016-06-10 2019-04-17 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1198386B (it) * 1982-07-06 1988-12-21 Lepetit Spa Un prodotto a rilascio protratto contenente il suloctidile
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4837111A (en) * 1988-03-21 1989-06-06 Alza Corporation Dosage form for dispensing drug for human therapy
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
ATE111351T1 (de) * 1990-07-23 1994-09-15 Alza Corp Oral anzuwendende osmotische vorrichtung zur abgabe von nicotin.

Also Published As

Publication number Publication date
MX9804008A (es) 1998-09-30
EP0862437A1 (en) 1998-09-09
CN1215993A (zh) 1999-05-05
NO982302D0 (no) 1998-05-20
OA10687A (en) 2002-11-27
AR004335A1 (es) 1998-11-04
WO1997018814A1 (en) 1997-05-29
TNSN96141A1 (fr) 2005-03-15
PE22898A1 (es) 1998-05-07
GB9523752D0 (en) 1996-01-24
JPH10513481A (ja) 1998-12-22
IS4706A (is) 1998-03-31
BR9611626A (pt) 1999-06-01
AP9600883A0 (en) 1997-01-31
TR199800902T2 (xx) 1998-09-21
CA2232715A1 (en) 1997-05-29
ZA969722B (en) 1998-05-20
HRP960554A2 (en) 1998-02-28
AU709560B2 (en) 1999-09-02
HUP9903734A3 (en) 2000-04-28
HUP9903734A2 (hu) 2000-03-28
PL326981A1 (en) 1998-11-09
CZ155498A3 (cs) 1999-03-17
AU7572196A (en) 1997-06-11
NO982302L (no) 1998-07-17
KR19990071505A (ko) 1999-09-27
CO4480020A1 (es) 1997-07-09
YU62096A (sh) 1999-03-04
SK63098A3 (en) 1999-05-07
NZ322053A (en) 1999-11-29
MA26410A1 (fr) 2004-12-20
AP718A (en) 1999-01-06

Similar Documents

Publication Publication Date Title
BG102438A (en) Medicamentous form
WO1996039156A3 (en) Phosphate-binding polymers for oral administration
WO1995005184A3 (en) Phosphate-binding polymers for oral administration
DE69432559D1 (de) Verwendung von eisenbindenden polymeren zur herstellung eines medikaments zur oralen verabreichung
CA2219991A1 (en) Taste masking pharmaceutical composition for oral administration
BG102313A (en) Method for the preparation of multilayer solid medicamentous forms for oral or rectal administration
AU1477697A (en) Pharmaceutical compressed tablet characterized by a high increase in volume by contact with biological fluids
WO1997038679A3 (en) Fast disintegrating oral dosage form
ATE232722T1 (de) Cyclosporin biologisch abbaubare mikro- und nanosphären mit gesteuerter freisetzung
AU2002243387A1 (en) Pharmaceutical dosage form for oral administration of low molecular weight heparin
WO1995022991A3 (en) Block copolymers
BG104620A (en) Oral pharmaceutical extended release dosage form
EP2233155A3 (en) Therapeutic polyanhydride compounds for drug delivery
CA2216437A1 (en) Pharmaceutical composition containing selected lanthanum carbonate hydrates
ATE290015T1 (de) Cyclosporinderivate, deren herstellung und pharmazeutische zubereitungen
AU3438897A (en) Stable drug form for oral administration and process for the preparation thereof
CA2034569A1 (en) Oral pharmaceutical forms of pimobendan
EE04606B1 (et) H+, K+-ATPaasi inhibiitori kasutamine ravimi valmistamiseks peroraalseks manustamiseks
CA2212309A1 (en) Extended-release solid oral dosage forms of drugs having low solubility in water
CA2038744A1 (en) Pharmaceutical composition containing slightly water-soluble drug
HK1008924A1 (en) Phosphate-binding polymers for oral administration
CA2219777A1 (en) Nanoparticles for oral administration of pharmaceutical agents of low solubility
GEP20063719B (en) Prevention of Migraine Recurrence
CA2209673A1 (en) Solid medicament form with active agent distributed in polymer material
GB9420748D0 (en) 1,5 benzodiazepine derivatives